{"doi":"10.1007/s00280-025-04840-2","title":"Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer","abstract":"PURPOSE: Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be effectively targeted by combining enzalutamide with the BCL-2 inhibitor venetoclax. EXPERIMENTAL DESIGN: This phase Ib single-arm trial of enzalutamide (160 mg/d) with venetoclax in patients with progressive mCRPC assessed dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Three dose levels (DL) of venetoclax (DL1 at 400 mg/d; DL2 at 600 mg/d; and DL3 at 800 mg/d) were evaluated using a 3 + 3 design. We also analyzed enzalutamide and venetoclax pharmacokinetics and conducted pharmacodynamic studies in peripheral blood mononuclear cells (PBMCs) to determine the impact of venetoclax on BCL-2 expression. RESULTS: A total of 10 patients were enrolled across 3 DL and no DLT was observed. Mean duration on treatment was 29 weeks (range: 8-140 weeks). Treatment-related adverse events (TRAEs) were mostly grade 1-2, and Grade 3 TRAEs included fatigue (10%) and thrombocytopenia (10%). 1/10 (10%) attained PSA50 response and 4/10 (40%) had stable disease. Estimated median overall survival (OS) was 19 months (95% CI 5-28 months) and median time to next systemic therapy (TNST) was 5 months (95% CI 1-35 months). Pharmacokinetic results revealed sub-optimal plasma levels of venetoclax. Pharmacodynamic studies demonstrated that venetoclax enhanced BCL-2β generation and promoted BCL-2 degradation. CONCLUSIONS: Enzalutamide with venetoclax has an acceptable toxicity profile in patients with mCRPC. Despite sub-optimal venetoclax levels, the treatment elicited pharmacodynamic and clinical response in a subset of patients. CLINICAL TRIAL ID: NCT03751436.","journal":"Cancer Chemotherapy and Pharmacology","year":2025,"id":524955,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":4,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9537,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03751436"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":630324,"name":"Anmbreen Jamroze","orcid":"0009-0006-0444-820X","position":1,"is_corresponding":false},{"id":570266,"name":"Dharmesh Gopalakrishnan","orcid":"0000-0003-3432-1155","position":2,"is_corresponding":false},{"id":320765,"name":"Rohit Jain","orcid":"0000-0002-4905-462X","position":3,"is_corresponding":false},{"id":898436,"name":"Changchuan Jiang","orcid":"0000-0002-7392-4154","position":4,"is_corresponding":false},{"id":743347,"name":"Julianne L. Holleran","orcid":"0000-0002-3738-8200","position":5,"is_corresponding":false},{"id":743348,"name":"Robert A. Parise","orcid":"0000-0003-4398-6271","position":6,"is_corresponding":false},{"id":485052,"name":"Robert R. Bies","orcid":"0000-0003-3818-2252","position":7,"is_corresponding":false},{"id":260289,"name":"David I. Quinn","orcid":"0000-0002-1411-0417","position":8,"is_corresponding":false},{"id":260451,"name":"Kristopher Attwood","orcid":"0000-0002-7229-5472","position":9,"is_corresponding":false},{"id":263774,"name":"Xiaozhuo Liu","orcid":"0000-0003-2237-1016","position":10,"is_corresponding":false},{"id":1119978,"name":"Kelly Green","orcid":"0000-0003-4827-3713","position":11,"is_corresponding":false},{"id":265393,"name":"Jason Kirk","orcid":null,"position":12,"is_corresponding":false},{"id":414176,"name":"Jan H. Beumer","orcid":"0000-0002-8978-9401","position":13,"is_corresponding":false},{"id":263780,"name":"Dean G. Tang","orcid":"0000-0001-5029-1174","position":14,"is_corresponding":false},{"id":294039,"name":"Gurkamal Chatta","orcid":"0000-0002-3154-9042","position":15,"is_corresponding":false},{"id":899071,"name":"Stuthi Perimbeti","orcid":null,"position":0,"is_corresponding":true}],"reference_count":53,"raw_metadata":null,"created_at":"2026-07-19T02:50:16.562292Z","pmid":"41315064","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}